BOSTON – Joslin Diabetes Center announced Martin (Marty) Pasqualini, Managing Director, CCA Group, has been elected to the position of Board Chair. Marty is a longtime supporter of Joslin and has served as a Trustee since 2019. In addition, three new members have been elected to Joslin’s Board of Trustees:

  • Ryan Enright, Managing Director, JLL
  • Bastiano Sanna, PhD, Executive Vice President, Chief of Cell and Genetic Therapies, Vertex Pharmaceuticals
  • Shunee Yee, President and CEO, CSOFT International and CSOFT Health Sciences

"We are thrilled to welcome Marty Pasqualini to the position of Board Chair and Ryan Enright, Bastiano Sanna, PhD, and Shunee Yee to our esteemed Board of Trustees," said Dr. Roberta Herman, President of Joslin Diabetes Center. " Under Marty’s leadership, we are confident the Board will continue to guide and support Joslin for years to come. Also, the collective and extensive expertise, diverse backgrounds, and shared commitments of Ryan, Bastiano and Shunee to Joslin’s mission will undoubtedly strengthen our organization's impact and drive us closer to our ultimate goal of finding a cure.”

The elections of the Board Chair and new Trustees become effective October 1, 2023.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Part of Beth Israel Lahey Health, Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is affiliated with Harvard Medical School and one of only 18 NIH-designated Diabetes Research Centers in the United States.

Media Relations Contact

Chloe Meck
cmeck [at] bilh.org (Email)